EMA Authorised: Tookad (padeliporfin di-potassium) — STEBA Biotech S.A

View source ↗

Summary

The EMA has authorised Tookad (padeliporfin di-potassium) for prostatic neoplasms, with STEBA Biotech S.A. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• TOOKAD (padeliparvovec? (Note: TOOKAD is verteporfin-based vascular-targeted photodynamic therapy).)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: STEBA Biotech S.A. Decision date: 07/12/2022